MYC and B-cell non-Hodgkin lymphoma: To expand the potential clinical utility of CCT245737 monotherapy we have shown that it has significant antitumor activity in an Eμ-Myc driven transgenic murine model of infiltrating B-cell lymphoma (Burkitt's-type lymphoma) [43].